TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• HER2 (Human Epidermal growth factor Receptor 2) is a tyrosine kinase receptor overexpressed in 25-30% of breast cancers.
• Trastuzumab, an anti-HER2 monoclonal antibody, shows efficacy in metastatic breast cancer but faces significant primary and acquired resistance.
• Mechanisms of Trastuzumab resistance, particularly impaired HER2 downregulation, are not fully understood.

Purpose of the Study:

• To investigate the role of mutations in HER2 and Cbl genes in Trastuzumab resistance.
• To explore alternative mechanisms, such as TGF-alpha (Transforming Growth Factor alpha), contributing to Trastuzumab unresponsiveness.
• To elucidate the impact of TGF-alpha on HER2 endocytosis and downregulation in breast cancer cells.

Main Methods:

• Genomic sequencing of HER2 and Cbl genes in 63 breast cancer samples.
• Analysis of TGF-alpha expression in paired tumor tissues before and after Trastuzumab treatment.
• In vitro experiments involving exogenous TGF-alpha expression in breast cancer cells to assess its effect on Trastuzumab-induced HER2 endocytosis and downregulation.

Main Results:

• No mutations were found in the critical HER2 and Cbl downregulation regions across the 63 breast cancer samples.
• Induction of TGF-alpha expression was observed in neoplastic tissue after Trastuzumab treatment in selected cases.
• In vitro, exogenous TGF-alpha significantly reduced Trastuzumab-induced HER2 endocytosis, downregulation, and cell growth inhibition.

Conclusions:

• Trastuzumab unresponsiveness is not primarily due to intrinsic defects in the HER2 downregulation machinery.
• TGF-alpha-mediated escape from HER2 downregulation represents a potential mechanism driving resistance to Trastuzumab therapy.
• Targeting TGF-alpha pathways may offer a strategy to overcome Trastuzumab resistance in HER2-positive breast cancer.